Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) insider Arturo Molina sold 2,718 shares of Protagonist Therapeutics stock in a transaction on Monday, November 16th. The stock was sold at an average price of $124.65, for a total transaction of $338,798.70. Following the sale, the insider directly owned 81,397 shares in the company, valued at $10,146,136.05. This trade represents a 3.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Protagonist Therapeutics Trading Down 0.1%
PTGX stock traded down $0.16 during trading on Tuesday, reaching $124.67. The stock had a trading volume of 583,063 shares, compared to its average volume of 603,332. The firm has a fifty day moving average price of $139.45 and a 200 day moving average price of $119.55. The company has a market capitalization of $8.14 billion, a P/E ratio of 26.45 and a beta of 1.21. Protagonist Therapeutics, Inc. has a 1-year low of $77.00 and a 1-year high of $160.81.
Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $3.07 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.57. The company had revenue of $274.41 million during the quarter, compared to the consensus estimate of $238.49 million. Protagonist Therapeutics had a return on equity of 42.83% and a net margin of 62.04%. Sell-side analysts predict that Protagonist Therapeutics, Inc. will post 5.52 EPS for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
PTGX has been the topic of several recent analyst reports. Weiss Ratings upgraded Protagonist Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, November 4th. Barclays raised their price objective on Protagonist Therapeutics from $153.00 to $180.00 and gave the company an “overweight” rating in a research note on Tuesday, September 1st. Wedbush restated an “outperform” rating on shares of Protagonist Therapeutics in a report on Monday, November 9th. TD Cowen lifted their price objective on Protagonist Therapeutics from $155.00 to $160.00 and gave the stock a “buy” rating in a report on Wednesday, October 21st. Finally, Leerink Partners assumed coverage on Protagonist Therapeutics in a research report on Monday, October 12th. They issued an “outperform” rating and a $190.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating and sixteen have given a Buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $166.67.
Get Our Latest Stock Analysis on Protagonist Therapeutics
Protagonist Therapeutics Company Profile
Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.
Read More
- Five stocks we like better than Protagonist Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
